Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid
09:18am, Friday, 14'th Nov 2025
A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center and initial acquirer Alkermes facing off with Lundbeck.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
08:17am, Friday, 14'th Nov 2025
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
Alkermes Response to Avadel Announcement
07:45am, Friday, 14'th Nov 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULAT
Avadel Receives Unsolicited Proposal from Lundbeck
05:45am, Friday, 14'th Nov 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
12:46pm, Wednesday, 12'th Nov 2025
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).
Alkermes' narcolepsy drug meets main goal in a mid-stage trial
07:35am, Wednesday, 12'th Nov 2025
Alkermes said on Wednesday its experimental narcolepsy drug met the main goals in a mid-stage study.
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
07:30am, Wednesday, 12'th Nov 2025
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton M
ALKS or ILMN: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 11'th Nov 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alkermes (ALKS) and Illumina (ILMN). But which of these two stocks presents investors with the better value op
The futures are trading mixed after a massive bounce-back rally on Monday across Wall Street, which saw all the major indices trade higher, with the NASDAQ closing up 2.27% at 23,554.
Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?
10:56am, Friday, 07'th Nov 2025
The consensus price target hints at a 36.3% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Alkermes to Participate in Two Upcoming Investor Conferences
04:00pm, Thursday, 06'th Nov 2025
DUBLIN , Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference Date/Time: T
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 06'th Nov 2025
Here is how Alkermes (ALKS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
FORM 8.1(a) & (b) (Opening Position Disclosure)
09:00am, Wednesday, 05'th Nov 2025
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 202
Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts
01:55am, Saturday, 01'st Nov 2025
Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen research firms that are covering the firm, Marketbeat.com repor
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
02:46pm, Wednesday, 29'th Oct 2025
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
